Temporal order of Alzheimer's disease-related cognitive marker changes in BLSA and WRAP longitudinal studies

Journal of Alzheimer's Disease

Volumn 59, Issue 4, 2017, Pages 1335-1347

  Bilgel, Murat ^a   Koscik, Rebecca L ^b   An, Yang ^a   Prince, Jerry L ^c   Resnick, Susan M ^a   Johnson, Sterling C ^b,d,e   Jedynak, Bruno M ^f  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c Johns Hopkins University   (United States)

^d WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f PORTLAND STATE UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; cognition; longitudinal studies; neuropsychological tests; preclinical

Indexed keywords

AGED; ALZHEIMER DISEASE; ARTICLE; ATTENTION; BOSTON NAMING TEST; COGNITION; CONTROLLED STUDY; DISEASE COURSE; EXECUTIVE FUNCTION; FEMALE; HUMAN; LANGUAGE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MARYLAND; MENTAL HEALTH; METHODOLOGY; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; REGISTER; SCORING SYSTEM; TRAIL MAKING TEST; VERBAL MEMORY; WISCONSIN; CLINICAL TRIAL; COGNITIVE DEFECT; COMPLICATION; DISEASE EXACERBATION; GENETICS; MULTICENTER STUDY; REPRODUCIBILITY; VERY ELDERLY;

APOLIPOPROTEIN E;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEINS E; BALTIMORE; COGNITION DISORDERS; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MENTAL STATUS SCHEDULE; NEUROPSYCHOLOGICAL TESTS; REGISTRIES; REPRODUCIBILITY OF RESULTS; WISCONSIN;

EID: 85027501110     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-170448     Document Type: Article

References (69)

1. Bäckman L, Jones S, Berger AK, Laukka EJ, Small BJ. (2005). Cognitive impairment in preclinical Alzheimer's disease: A meta-analysis. Neuropsychology 19, 520-531
2. Grober E, Hall CB, Lipton RB, Zonderman AB, Resnick SM, Kawas C. (2008). Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease. J Int Neuropsychol Soc 14, 266-278
3. Kawas CH, Corrada MM, Brookmeyer R, Morrison A, Resnick SM, Zonderman AB, Arenberg D. (2003). Visual memory predicts Alzheimer's disease more than a decade before diagnosis. Neurology 60, 1089-1093
4. Elias MF, Beiser A, Wolf PA, Au R, White RF, D'Agostino RB. (2000). The preclinical phase of Alzheimer disease: A 22-year prospective study of the Framingham Cohort. Arch Neurol 57, 808-813
5. Hedden T, Oh H, Younger AP, Patel TA. (2013). Metaanalysis of amyloid-cognition relations in cognitively normal older adults. Neurology 80, 1341-1348
6. Johnson SC, Christian BT, Okonkwo OC, Oh JM, Harding S, Xu G, Hillmer AT, Wooten DW, Murali D, Barnhart TE, Hall LT, Racine AM, Klunk WE, Mathis CA, Bendlin BB, Gallagher CL, Carlsson CM, Rowley HA, Hermann BP, Dowling NM, Asthana S, Sager MA. (2014). Amyloid burden and neural function in people at risk for Alzheimer's Disease. Neurobiol Aging 35, 576-584
7. Perrotin A, Mormino EC, Madison CM, Hayenga AO, Jagust WJ. (2012). Subjective cognition and amyloid deposition imaging: A Pittsburgh compound B positron emission tomography study in normal elderly individuals. Arch Neurol 69, 223-229
8. Song Z, Insel PS, Buckley S, Yohannes S, Mezher A, Simonson A, Wilkins S, Tosun D, Mueller S, Kramer JH, Miller BL, Weiner MW. (2015). Brain amyloid-burden is associated with disruption of intrinsic functional connectivity within the medial temporal lobe in cognitively normal elderly. J Neurosci 35, 3240-3247
9. Amariglio RE, Becker JA, Carmasin J, Wadsworth LP, Lorius N, Sullivan C, Maye JE, Gidicsin C, Pepin LC, Sperling RA, Johnson KA, Rentz DM. (2012). Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia 50, 2880-2886
10. Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, Grundman M, Sabbagh MN, Sadowsky CH, Fleisher AS, Carpenter A, Clark CM, Joshi AD, Mintun MA, Skovronsky DM, Pontecorvo MJ. (2012). Amyloid-assessed by florbetapir F 18 PET and 18-month cognitive decline: Amulticenter study. Neurology 79, 1636-1644
11. Sperling RA, Johnson KA, Doraiswamy PM, Reiman EM, Fleisher AS, Sabbagh MN, Sadowsky CH, Carpenter A, Davis MD, Lu M, Flitter M, Joshi AD, Clark CM, Grundman M, Mintun MA, Skovronsky DM, Pontecorvo MJ. (2013). Amyloid deposition detected with florbetapir F 18 (18FAV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging 34, 822-831
12. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. (2011). Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 280-292
13. Lim YY, Maruff P, Pietrzak RH, Ames D, Ellis KA, Harrington K, Lautenschlager NT, Szoeke C, Martins RN, Masters CL, Villemagne VL, Rowe CC, AIBL Research Group. (2014). Effect of amyloid on memory and nonmemory decline from preclinical to clinical Alzheimer's disease. Brain 137, 221-231
14. Lim YY, Villemagne VL, Pietrzak RH, Ames D, Ellis KA, Harrington K, Snyder PJ, Martins RN, Masters CL, Rowe CC, Maruff P. (2015). APOE 4 moderates amyloid-related memory decline in preclinical Alzheimer's disease. Neurobiol Aging 36, 1239-1244
15. Mormino EC, Betensky RA, Hedden T, Schultz AP, Ward A, Huijbers W, Rentz DM, Johnson KA, Sperling RA. (2014). Amyloid and APOE 4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology 82, 1760-1767
16. Pietrzak RH, Lim YY, Neumeister A, Ames D, Ellis KA, Harrington K, Lautenschlager NT, Restrepo C, Martins RN, Masters CL, Villemagne VL, Rowe CC, Maruff P. (2015). Amyloid-, anxiety, and cognitive decline in preclinical Alzheimer disease: A multicenter, prospective cohort study. JAMA Psychiatry 72, 284-291
17. Roe C, Fagan A, Grant E, Hassenstab J, Moulder K, Dreyfus DM, Sutphen C, Benzinger T, Mintun M, Holtzman D, Morris J. (2013). Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 80, 1784-1791
18. Stonnington CM, Chen K, Lee W, Locke DEC, Dueck AC, Liu X, Roontiva A, Fleisher AS, Caselli RJ, Reiman EM. (2014). Fibrillar amyloid correlates of preclinical cognitive decline. Alzheimers Dement 10, e1-e8
19. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL. (2013). Amyloid deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol 12, 357-367
20. Yotter RA, Doshi J, Clark V, Sojkova J, Zhou Y, Wong DF, Ferrucci L, Resnick SM, Davatzikos C. (2013). Memory decline shows stronger associations with estimated spatial patterns of amyloid deposition progression than total amyloid burden. Neurobiol Aging 34, 2835-2842
21. Resnick SM, Sojkova J, Zhou Y, An Y, Ye W, Holt DP, Dannals RF, Mathis CA, Klunk WE, Ferrucci L, Kraut MA, Wong DF. (2010). Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]Pi B. Neurology 74, 807-815
22. Besson FL, La Joie R, Doeuvre L, Gaubert M, Mezenge F, Egret S, Landeau B, Barre L, Abbas A, Ibazizene M, de La Sayette V, Desgranges B, Eustache F, Chetelat G. (2015). Cognitive and brain profiles associated with current neuroimaging biomarkers of preclinical Alzheimer's disease. J Neurosci 35, 10402-10411
23. Toledo JB, Bjerke M, Chen K, Rozycki M, Jack CR Jr, Weiner MW, Arnold SE, Reiman EM, Davatzikos C, Shaw LM, Trojanowski JQ, Alzheimer's Disease Neuroimaging Inititaive. (2015). Memory, executive, and multidomain subtle cognitive impairment: Clinical and biomarker findings. Neurology 85, 144-153
24. Wirth M, Villeneuve S, Haase CM, Madison CM, Oh H, Landau SM, Rabinovici GD, Jagust WJ. (2013). Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol 70, 1512-1519
25. Doré V, Villemagne VL, Bourgeat P, Fripp J, Acosta O, Chetélat G, Zhou L, Martins R, Ellis KA, Masters CL, Ames D, Salvado O, Rowe CC. (2013). Cross-sectional and longitudinal analysis of the relationship between A deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. JAMA Neurol 70, 903-911
26. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. (2005). Molecular, structural, and functional characterization of Alzheimer's disease: Evidence for a relationship between default activity, amyloid, and memory. J Neurosci 25, 7709-7717
27. Fleisher AS, Sherzai A, Taylor C, Langbaum JB, Chen K, Buxton RB. (2009). Resting-state BOLD networks versus task-associated functional MRI for distinguishing Alzheimer's disease risk groups. Neuroimage 47, 1678-1690
28. Kennedy KM, Rodrigue KM, Devous MD, Hebrank AC, Bischof GN, Park DC. (2012). Effects of beta-amyloid accumulation on neural function during encoding across the adult lifespan. Neuroimage 62, 1-8
29. Oh H, Madison C, Villeneuve S, Markley C, Jagust WJ. (2014). Association of gray matter atrophy with age,-amyloid, and cognition in aging. Cereb Cortex 24, 1609-1618
30. Ahn HJ, Seo SW, Chin J, Suh MK, Lee BH, Kim ST, Im K, Lee JM, Lee JH, Heilman KM, Na DL. (2011). The cortical neuroanatomy of neuropsychological deficits in mild cognitive impairment and Alzheimer's disease: A surface-based morphometric analysis. Neuropsychologia 49, 3931-3945
31. Schiratti JB, Allassonniere S, Colliot O, Durrleman S. (2015). Learning spatiotemporal trajectories from manifold-valued longitudinal data. In Advances in Neural Information Processing Systems 28, Cortes C, Lawrence ND, Lee DD, Sugiyama M, Garnett R, eds. pp. 2395-2403
32. Schulam P, Wigley F, Saria S. (2015). Clustering longitudinal clinical marker trajectories from electronic health data: Applications to phenotyping and endotype discovery. In AAAI Conference on Artificial Intelligence, pp. 2956-2964
33. Donohue MC, Jacqmin-Gadda H, Le Goff M, Thomas RG, Raman R, Gamst AC, Beckett LA, Jack CR Jr, Weiner MW, Dartigues JF, Aisen PS, Alzheimer's Disease Neuroimaging Initiative. (2014). Estimating long-term multivariate progression from short-term data. Alzheimers Dement 10, S400-S410
34. Schmidt-Richberg A, Guerrero R, Ledig C, Molina-Abril H, Frangi AF, Rueckert D, Alzheimer's Disease Neuroimaging Initiative. (2015). Multi-stage biomarker models for progression estimation in Alzheimer's disease. Inf Process Med Imaging 24, 387-398
35. Young AL, Oxtoby NP, Daga P, Cash DM, Fox NC, Ourselin S, Schott JM, Alexander DC. (2014). A data-driven model of biomarker changes in sporadic Alzheimer's disease. Brain 137, 2564-2577
36. Jedynak BM, Lang A, Liu B, Katz E, Zhang Y, Wyman BT, Raunig D, Jedynak CP, Caffo B, Prince JL. (2012). A computational neurodegenerative disease progression score: Method and results with the Alzheimer's Disease Neuroimaging Initiative cohort. Neuroimage 63, 1478-1486
37. Bilgel M, Prince JL, Wong DF, Resnick SM, Jedynak BM. (2016). Amultivariate nonlinear mixed effects model for longitudinal image analysis: Application to amyloid imaging. Neuroimage 134, 658-670
38. Shock NW, Greulich RC, Andres R, Arenberg D, Costa PT Jr, Lakatta EG, Tobin JD. (1984). Normal human aging: The Baltimore Longitudinal Study of Aging, U.S. Government Printing Office, Washington, DC
39. Sager MA, Hermann B, La Rue A. (2005). Middle-aged children of persons with Alzheimer's disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. J Geriatr Psychiatry Neurol 18, 245-249
40. Reitan RM. (1992). Trail making test: Manual for administration and scoring, Reitan Neuropsychological Laboratory, Tucson, AZ
41. Wechsler D. (1981). Wechsler adult intelligence scalerevised, Psychological Corporation, San Antonio, TX
42. Wechsler D. (1997). Wechsler adult intelligence scale, The Psychological Corporation, San Antonio, TX
43. Delis DC, Kramer JH, Kaplan E, Ober BA. (1987). The California verbal learning test, Psychological Corporation, San Antonio, TX
44. Lezak M, Howieson D, Loring DW. (2004). Neuropsychological assessment, Oxford University Press, London
45. Kaplan E, Goodglass H, Weintraub S. (1983). Boston naming test, Lea & Febiger, Philadelphia, PA
46. Folstein MF, Folstein SE, McHugh PR. (1975). Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198
47. Newcombe F. (1969). Missile wounds of the brain: A study of psychological deficits, Oxford University Press, Oxford, UK
48. Fuld PA. (1978). Psychological testing in the differential diagnosis of the dementias. In Alzheimer's disease: Senile dementia and related disorders, Katzman R, Terry RD, Bick KL, eds. Raven Press, New York, NY, pp. 185-193
49. Morris JC. (1993). The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43, 2412-2414
50. American Psychiatric Association. (1987). Diagnostic and Statistical Manual of Mental Disorders: DSM-III-R, American Psychiatric Association, Washington, DC
51. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. (1984). Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944
52. Petersen RC. (2004). Mild cognitive impairment as a diagnostic entity. J Intern Med 256, 183-194
53. Clark LR, Koscik RL, Nicholas CR, Okonkwo OC, Engelman CD, Bratzke LC, Hogan KJ, Mueller KD, Bendlin BB, Carlsson CM, Asthana S, Sager MA, Hermann BP, Johnson SC. (2016). Mild Cognitive Impairment in late middle age in the Wisconsin Registry for Alzheimer's Prevention (WRAP) study: Prevalence and characteristics using robust and standard neuropsychological normative data. Arch Clin Neuropsychol 31, 675-688
54. Koscik RL, La Rue A, Jonaitis EM, Okonkwo OC, Johnson SC, Bendlin BB, Hermann BP, Sager MA. (2014). Emergence of mild cognitive impairment in late middle-aged adults in theWisconsin Registry for Alzheimer's Prevention. Dement Geriatr Cogn Disord 38, 16-30
55. Wechsler D. (1987). Wechsler memory scale-revised, Psychological Corporation, San Antonio, TX
56. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR Jr, Jagust WJ, Shaw LM, Toga AW. (2010). Alzheimer's Disease Neuroimaging Initiative (ADNI) clinical characterization. Neurology 74, 201-209
57. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. (2011). The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 270-279
58. Clark LR, Racine AM, Koscik RL, Okonkwo OC, Engelman CD, Carlsson CM, Asthana S, Bendlin BB, Chappell R, Nicholas CR, Rowley HA, Oh JM, Hermann BP, Sager MA, Christian BT, Johnson SC. (2016). Beta-amyloid and cognitive decline in late middle age: Findings from theWisconsin Registry for Alzheimer's Prevention study. Alzheimers Dement 12, 805-814
59. McCarrey AC, An Y, Kitner-Triolo MH, Ferrucci L, Resnick SM. (2016). Sex differences in cognitive trajectories in clinically normal older adults. Psychol Aging 31, 166-175
60. Corder EH, Lannfelt L, Bogdanovic N, Fratiglioni L, Mori H. (1998). The role of APOE polymorphisms in late-onset dementias. Cell Mol Life Sci 54, 928-934
61. Liu CC, Kanekiyo T, Xu H, Bu G. (2013). Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol 9, 106-118
62. Kurt P, Yener G, Oguz M. (2011). Impaired digit span can predict further cognitive decline in older people with subjective memory complaint: A preliminary result. Aging Ment Health 15, 364-369
63. Monsell SE, Mock C, Hassenstab J, Roe CM, Cairns NJ, Morris JC, Kukull W. (2014). Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology. Neurology 83, 434-440
64. Kiewel NA, Wisdom NM, Bradshaw MR, Pastorek NJ, Strutt AM. (2012). A retrospective review of digit spanrelated effort indicators in probable Alzheimer's disease patients. Clin Neuropsychol 26, 965-974
65. Loring DW, Goldstein FC, Chen C, Drane DL, Lah JJ, Zhao L, Larrabee GJ. (2016). False-positive error rates for reliable digit span and auditory verbal learning test performance validity measures in amnestic mild cognitive impairment and early Alzheimer disease. Arch Clin Neuropsychol 31, 313-331
66. Bossers WJ, van Der Woude LH, Boersma F, Scherder EJ, van Heuvelen MJ. (2012). Recommended measures for the assessment of cognitive and physical performance in older patients with dementia: A systematic review. Dement Geriatr Cogn Dis Extra 2, 589-609
67. Hoshi Y, Oda I, Wada Y, Ito Y, Yamashita Y, Oda M, Ohta K, Yamada Y, Tamura M. (2000). Visuospatial imagery is a fruitful strategy for the digit span backward task: A study with near-infrared optical tomography. Cogn Brain Res 9, 339-342
68. Gerton BK, Brown TT, Meyer-Lindenberg A, Kohn P, Holt JL, Olsen RK, Berman KF. (2004). Shared and distinct neurophysiological components of the digits forward and backward tasks as revealed by functional neuroimaging. Neuropsychologia 42, 1781-1787
69. Aleman A, van't Wout M. (2008). Repetitive transcranial magnetic stimulation over the right dorsolateral prefrontal cortex disrupts digit span task performance. Neuropsychobiology 57, 44-48